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Parathyroid hormone-related peptide is a regulatory protein implicated in the pathogenesis of bone metastases, particularly in
breast carcinoma. Parathyroid hormone-related peptide is widely expressed in primary prostate cancers but there are few
reports of its expression in prostatic metastases. The aim of this study was to examine the expression of parathyroid hormone-
related peptide and its receptor in matched primary and in bone metastatic tissue from patients with untreated adenocarcinoma
of the prostate. Eight-millimetre trephine iliac crest bone biopsies containing metastatic prostate cancer were obtained from 14
patients from whom matched primary tumour tissue was also available. Histological grading was performed by an independent
pathologist. The cellular location of mRNA for parathyroid hormone-related peptide and parathyroid hormone-related peptide
receptor was identiﬁed using in situ hybridization with
35S-labelled probe. Expression of parathyroid hormone-related peptide
and its receptor was described as uniform, heterogenous or negative within the tumour cell population. Parathyroid hormone-
related peptide expression was positive in 13 out of 14 primary tumours and in all 14 metastases. Receptor expression was
evident in all 14 primaries and 12 out of 14 metastases. Co-expression of parathyroid hormone-related peptide and parathyroid
hormone-related peptide receptor was common (13 primary tumours, 12 metastases). The co-expression of parathyroid
hormone-related peptide and its receptor suggest that autocrine parathyroid hormone-related peptide mediated stimulation
may be a mechanism of escape from normal growth regulatory pathways. The high frequency of parathyroid hormone-related
peptide expression in metastases is consistent with a role in the pathogenesis of bone metastases.
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Despite increasing detection and treatment of early prostate cancer,
this disease still accounts for 9000 deaths annually in England and
Wales (Ofﬁce for National Statistics, 1998). The development of
bone metastases is undoubtedly a major cause of morbidity and
mortality; patients presenting with osseous involvement have a
mean survival of just 2.5 years (George, 1988).
The overwhelming majority of prostate cancer bone metastases
are osteoblastic, characterized by increased rates of lamellar bone
resorption and replacement with abnormal woven bone. Therefore,
in common with osteolytic metastases, osteoclast activation is a key
step in the pathogenesis of osteoblastic bone metastases (Clarke et
al, 1991, 1993). Consequently osteo-active cytokines and growth
factors produced by cancer cells may inﬂuence the tropism of
certain tumours for metastasis to bone, and offer an advantage
in the genesis of bony secondaries.
Parathyroid hormone related peptide (PTHrP) is a protein with
N-terminal homology to PTH (Guise et al, 1997). It is able to bind
to and activate the PTH receptor and is consequently a potent
stimulant of osteoclasts and osteoblasts (Abou-Samra et al, 1992).
Work in breast carcinoma has suggested that PTHrP may be an
important factor in bone metastasis. Serum PTHrP levels are
elevated in patients with bone metastases (Bundred et al, 1991)
and that there is up regulation of PTHrP expression in the meta-
static tissue (Powell et al, 1991). Additionally there are also found
to be high levels of expression of the receptor for PTHrP in breast
cancer bone metastases (Downey et al, 1996).
PTHrP is expressed in benign prostate, although its function is
unclear (Cramer et al, 1996). In primary prostate cancer PTHrP
staining intensity increases with tumour grade (Asadi et al,
1996), and in vitro cell line studies have suggested that it may be
a signiﬁcant autocrine growth factor (Iwamura et al, 1994a). Draw-
ing on the work in breast cancer and the parallels between the two
tumours, it has been suggested that PTHrP may be a potential
factor in the pathogenesis of prostate cancer bone metastases
(Guise, 1997).
It is hypothesized that expression of PTHrP and PTHrP receptor
(PTHrPr) offer an advantage in the genesis of bone metastases in
prostate cancer through paracrine and autocrine mechanisms.
The aim of this study was to test this hypothesis by investigation
of the co-expression of PTHrP and PTHrP receptor in matched
pairs of untreated primary prostate cancer and their corresponding
bone metastases.
MATERIALS AND METHODS
Having obtained informed consent, iliac crest bone biopsies were
taken from men known or strongly suspected to have untreated
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also available. Local Ethics Committee approval was granted for the
study. All specimens were ﬁxed in formalin and the bone biopsies
decalciﬁed in EDTA. All tissue was embedded in parafﬁn wax. On
analysis of the bone specimens 14 were found to contain metastatic
prostate cancer. All primary and metastatic tumours were graded
according to the Gleason system (Gleason and Mellinger, 1974)
by an independent pathologist.
The expression of PTHrP and PTHrPr were determined by in
situ hybridization on 7 mm tissue sections. The cDNA probes were
kind gifts to the Department of Osteoarticular Pathology from Dr
MT Gillespie (St Vincent’s Institute for Medical Research, Victoria,
Australia) and Dr E Schipani (Massachusetts General Hospital,
MA, USA) respectively.
Probe labelling
Radioactive labelling of the probe using
35S was achieved using the
Amersham Megaprime
TM DNA labelling system. The probe and
primer were mixed, then the double stranded DNA probe dena-
tured by immersion in a boiling bath. The labelling reaction was
initiated by mixing the denatured DNA, reaction buffer, unlabelled
deoxynucleotide triphosphate,
35S-deoxycytosine triphosphate, and
Kenlow fragment of DNA polymerase. Following incubation at
378C for 1 h, the reaction was stopped by the addition of 0.2 M
EDTA pH 8.0. The labelled probe was then puriﬁed by centrifuga-
tion.
Prehybridization
Following dewaxing, tissue sections mounted on sialane coated
slides were subjected to the following procedures. Tissue permeabi-
lization was carried out by incubation with proteinase K for 1 h
(5 mgm l
71 for prostate and 10 mgm l
71 for bone sections).
Control sections were created by elimination of the hybridization
signal by incubation for 2 h at 378C with RNase A. Post-ﬁxation
was carried out in 0.4% paraformaldehyde at 48C.
Hybridization
The hybridization buffer containing the
35S-labelled probe was
applied to all tissue sections and then incubated overnight at 378C.
Post-hybridization washes
A series of progressively higher stringency washes were performed,
using 0.56SSC/1 mM EDTA/10 mM Dithiolthreitol, then
0.56SSC/1 mM EDTA, and then in 50% formamide:50% 0.15 M
NaCl/5 mM Tris pH 7.4/0.5 mM EDTA pH 8.0, (SSC – standard
saline citrate solution: 7.5 mM NaCl/0.75 mM NaCitrate). Final
washes were then performed in 0.56SSC, initially at 558C then
at room temperature. Sections were dehydrated in industrial
methylated spirit and air dried.
Detection
Binding of the radiolabelled probe was detected by autoradio-
graphy. After exposure at 48C for 2–3 weeks to a layer of
Ilford K5 emulsion, slides were developed using Ilford D-19
developer, and ﬁxed with Ilford Hypam. Sections were counter
stained with Mayer’s haematoxylin, dehydrated and mounted
with Xam.
Analysis
Precipitation of the silver granules produced by autoradiography
was assessed using a Leitz Laborlux 12 microscope with the 620
objective lens, with transmitted light and dark ﬁeld condensers.
The distribution of signal across the tumour cell was described
as uniform, heterogeneous or negative.
RESULTS
Only three of the primary tumours were moderately differentiated,
the remainder being poorly differentiated (Gleason 58). All metas-
tases were poorly differentiated. The distribution of tumour grades
are shown in Table 1.
PTHrP expression was positive in 13 out of 14 primary tumours
and in all 14 metastases. PTHrP expression was greater in the
metastases than the primary tumours. Uniform staining was
detected in 11 cases, three metastases exhibited heterogeneous
staining, and in no case was PTHrP staining negative. Receptor
expression was evident in all 14 primaries and 12 out of 14 metas-
tases. The majority of primary tumours (85%) had uniform
expression, while seven and ﬁve metastases had uniform (Figure
1) and heterogeneous staining respectively. In eight cases there
was similar expression levels of PTHrP receptor in the paired
tumours, while in six cases there was down regulation of receptor
expression in the metastatic prostate cells. The patterns of PTHrP
and PTHrP receptor expression in the specimens are summarized
in Table 2.
DISCUSSION
Animal models of bone metastasis have demonstrated the impor-
tance of PTHrP in the metastatic cascade. The activation of
osteoclasts by PTHrP in conjunction with interleukin 1 has been
shown to be essential for bone metastasis development (Arguello
et al, 1988). In mice inoculated with highly metastatic breast and
lung cancer cell lines, treatment with an anti-PTHrP antibody,
reduced both tumour burden and osteoclastic bone resorption
(Guise et al, 1996; Iguchi et al, 1996).
PTHrP has been most extensively investigated in breast carcino-
ma, where 60% of primary tumours are found to have positive
expression of PTHrP (Southby et al, 1990; Bundred et al, 1992).
In metastases in soft tissues only 17% are positive for PTHrP in
contrast to 92% of those in bone (Powell et al, 1991). These ﬁnd-
ings support the view that PTHrP has a role in the development
and progression of bone metastases.
Although PTHrP is expressed in normal prostate (Cramer et al,
1996), benign prostatic epithelial cells do not show enhancement of
growth in the presence of PTHrP in tissue culture (Peehl et al,
1997). PTHrP is secreted by all three commonly studied human
malignant prostatic cell lines (PC3, DU-145, and LNCaP) and
levels are highest in the bone metastasis derived PC3 line (Iwamura
et al, 1994a). The same study demonstrated that culture with
synthetic PTHrP led to increased proliferation of PC3 and DU-
145 cells (Iwamura et al, 1994a), suggesting that PTHrP may be
a signiﬁcant autocrine factor in prostate tumour growth, particu-
larly in bone metastases.
PTHrP expression in primary prostatic carcinoma is common
(Iwamura et al, 1993; Lee et al, 1997). Lymph node metastases
exhibit similar levels of PTHrP expression to those of poorly differ-
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Table 1 Distribution of Gleason score in the matched untreated primary
prostate cancers and corresponding bone metatases
No. of tumours
Gleason score Primary prostate cancers Bone metastases
51
72
84 2
95 4
10 2 8
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for PTHrP was detected in all 14 primary prostate tumours,
although expression was heterogeneous in four cases. In the corre-
sponding bone metastases, all 14 were positively staining, all but
three being uniformly stained. Previous studies of 10 (Bryden et
al, 2002) and 14 (Iddon et al, 2000) archival prostatic bone metas-
tases by immunohistochemistry have demonstrated PTHrP
expression in only 50% of samples. Differences in the technique
of PTHrP detection are unlikely to account for this, as concordance
between immunohistochemistry and in-situ hybridization for
detection of PTHrP has been described (Iwamura et al, 1994b)
suggesting that PTHrP expression is regulated at the gene level.
This difference may be due to variation in PTHrP expression with
tumour grade as described for primary prostate carcinoma
(Iwamura et al, 1993). In our previous study 7 out of 10 specimens
contained well or moderately differentiated tumour (Bryden et al,
2002), and lower levels of PTHrP expression might be anticipated
than in the exclusively poorly differentiated group of prospectively
collected metastases. In the series investigated by Iddon et al
(2000), neither the differentiation of the metastases, nor their treat-
ment status (untreated, hormone manipulated or escaped
hormonal control) is described, and it is therefore difﬁcult to
comment given these variables. It must also be considered that
the sample sizes are small and that the differences in levels of
PTHrP expression might simply represent true variation.
Despite the proposed importance of PTHrP in the development
of prostatic bone metastases, paradoxically, hypercalcaemia is
found in less than 2% of patients. In contrast to this, hypercalcae-
mia is seen in up to 20% of breast cancer sufferers with bone
metastases (Coleman and Reubens, 1987). Hypercalcaemia may
be partially accounted for by the release of bone bound calcium
from lytic deposits, and conversely in the sclerotic metastases of
prostate cancer there is calcium ‘bone hunger’ for new bone forma-
tion, which may even lead to secondary hyperparathyroidism
(Minisola et al, 1987). However the humoural contribution of
PTHrP to calcium homeostasis derangement is well described in
breast cancer, and the detection of PTHrP is strongly correlated
with hypercalcaemia (Bundred et al, 1991). Few studies have inves-
tigated the serum levels of PTHrP in prostate cancer speciﬁcally
but levels have been found to be similar to those in normocalcae-
mic patients without malignancy (Kao et al, 1990). This would be
consistent with the variable secretion of PTHrP into the serum
from tumours in which PTHrP can be detected (Dunne et al,
1993). Consequently the autocrine/paracrine effects of PTHrP are
not universally coupled to the humoural effects.
Staining of the same specimens for the receptor for PTHrP
was positive in all 14 primary prostate tumours and expression
was heterogeneous in only two cases. In the bone metastases,
12 of 14 stained positively, but in six staining was heterogeneous.
The role of the PTHrP receptor has not previously been
described clearly in benign or malignant human prostate tissue.
Immuno-histochemistry has failed to demonstrate the PTHrP
receptor in the canine model of benign prostate (Blomme et
al, 1998), which would be consistent with the lack of growth
factor response to PTHrP found in benign prostate by Peehl et
al (1997).
The high levels of PTHrP receptor demonstrated in this study in
primary (100%) and metastatic (85%) prostate cancer are similar
to those described in breast carcinoma, where PTHrP receptor
can be detected in 61–96% of tumours (Carron et al, 1997;
Downey et al, 1997; Iezzoni et al, 1998) using in-situ hybridization
or PCR. There are no comparable data for prostate cancers avail-
able. However for PTHrP to have an autocrine or paracrine
effect, it is logical that the PTHrP receptor would need to be
expressed within the tissue. PTHrP does not appear to act as a
growth factor in benign tissue (Peehl et al, 1997), consequently it
might be hypothesized that development of PTHrP receptor
expression is a signiﬁcant component of the malignant phenotype.
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Figure 1 Section of prostatic bone metastasis having undergone in-situ
hybridization with the probe for PTHrP receptor. Micrograph (A) standard
light ground ﬁeld, stained with H&E, and micrograph (B) is the same sec-
tion but with dark ground ﬁeld, and the silver grains show as the bright
spots. The distribution of the bright spots over the metastatic cells indicate
uniform signal for PTHrP receptor.
Table 2 Distribution of PTHrP and PTHrP receptor expression in 14 pairs of untreated primary
prostate cancer and matched bone metastases
Expression of PTHrP or PTHrP receptor
Primary tumour Bone metastasis
Uniform Heterogenous Negative Uniform Heterogenous Negative
PTHtrP 9 4 1 11 3
PTHrP receptor 12 2 7 5 2
PTHrP and receptor in prostate cancer and bone metastases
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British Journal of Cancer (2002) 86(3), 322–325 ã 2002 The Cancer Research CampaignOverall, this study has shown a high level of expression of
PTHrP and its receptor in bone metastases of prostate cancer
and their corresponding primary tumours. This supports the
previously described work in prostate and other tumour systems,
proposing that PTHrP is a likely mediator predisposing to the
formation of bone metastases. The co-expression of PTHrP and
its receptor would suggest that PTHrP is able to act as an autocrine
and/or paracrine growth factor in prostate cancer.
Further work to deﬁne and investigate the expression of the
PTHrP receptor in benign and malignant prostatic tissue would
be important to determine whether this is a feature exclusive to
malignant prostatic cells and whether there is any temporal rela-
tionship to the presence of bone metastases.
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